Intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer.

Abstract:

OBJECTIVES:To report the intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer. MATERIALS AND METHODS:Ninety-two patients with cervical cancer (stage IB-IVA, according to FIGO staging), were treated by curative radiotherapy from February 2012 to June 2015. All patients were treated with whole pelvic radiotherapy to 50 Gy in 25 fractions and central shielding after 44 Gy, in combination with TAUS-guided brachytherapy, in order to escalate the total dose (EQD2) to the minimal dose at cervical points (in EQD2 concepts) defined by TAUS, while maintaining low doses to ICRU bladder and rectal points. The treatment results and toxicity profiles were reported. RESULTS:At median follow-up time of 41.2 months (range 8 to 61 months) the pelvic control, disease-free survival, and overall survival rates were 84.8%, 75%, and 88%, respectively. The mean applied doses to cervix, bladder, and rectal points were 83.5, 72.3, and 76.5 Gy, respectively. Eight patients developed grade 2 Gastrointestinal toxicity. CONCLUSION:The 3-year results demonstrated that TAUS-guided brachytherapy is feasible and associated with excellent tumor control/toxicity rates in cervical cancer.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Tharavichitkul E,Chakrabandhu S,Klunklin P,Onchan W,Jia-Mahasap B,Wanwilairat S,Tippanya D,Jayasvasti R,Sripan P,Galalae RM,Chitapanarux I

doi

10.1016/j.ygyno.2018.01.015

subject

Has Abstract

pub_date

2018-03-01 00:00:00

pages

468-473

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(18)30047-7

journal_volume

148

pub_type

杂志文章
  • Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.

    abstract::The optimal treatment of early-stage ovarian borderline tumors is controversial. Only a few randomized trials evaluating adjuvant treatment for this disease have been published. Between 1970 and 1988 four consecutive randomized trials, including patients with ovarian borderline tumors, were conducted at the Norwegian ...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1006/gyno.1993.1279

    authors: Tropé C,Kaern J,Vergote IB,Kristensen G,Abeler V

    更新日期:1993-11-01 00:00:00

  • Diagnosis of endometrial cancer in patients with postmenopausal bleeding by analysis of the lactate dehydrogenase isoenzyme activity profile in uterine fluid.

    abstract:OBJECTIVES:We have previously shown that high activity of lactate dehydrogenase (LD) isoenzymes 4 and 5 in terine aspirates is a marker for endometrial carcinoma. The purpose of this study was to identify an abnormal activity profile of LD2-5 using LD1 as an internal standard, thereby being able to dispense with measur...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.02.014

    authors: Niklasson O,Skude G,Marsal K,Casslén B

    更新日期:2004-05-01 00:00:00

  • Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.

    abstract::Favorable responses to hexamethylmelamine (HMM) have been documented in untreated as well as in alkylating agent-resistant ovarian epithelial adenocarcinoma (OvCa). Platinum-based combination therapy for OvCa has been used since 1976. Eighteen patients with OvCa were treated with HMM as salvage therapy between Februar...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(84)90076-3

    authors: Stehman FB,Ehrlich CE,Callangan MF

    更新日期:1984-02-01 00:00:00

  • Cell kinetics: a prognostic marker in epithelial ovarian cancer.

    abstract::The proliferative activities (3H-thymidine labeling index, LI) of 72 primary ovarian cancers and 76 metastatic lesions from untreated patients were evaluated. Overall, median LI values for primary and metastatic lesions were similar (7.8 vs 7.0%), but cell kinetics significantly differed in metastases from different s...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0090-8258(89)90003-6

    authors: Silvestrini R,Daidone MG,Bolis G,Fontanelli R,Landoni F,Andreola S,Colombi R

    更新日期:1989-10-01 00:00:00

  • The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.

    abstract:OBJECTIVE:The opioid growth factor (OGF) and its receptor, OGFr, serve as a tonically active inhibitory axis regulating cell proliferation in normal cells and a variety of cancers, including human ovarian cancer. Blockade of OGF and OGFr with the nonselective opioid receptor antagonist naltrexone (NTX) upregulates expr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.04.009

    authors: Donahue RN,McLaughlin PJ,Zagon IS

    更新日期:2011-08-01 00:00:00

  • Reply.

    abstract::Copyright ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5026

    authors: Kodama J,Yoshinouchi M

    更新日期:1998-07-01 00:00:00

  • Comparison of two Lynch screening strategies in endometrial cancer in a California health system.

    abstract:OBJECTIVE:Compare detection of Lynch syndrome in endometrial cancer between regions of a health care system with different screening strategies. METHODS:A retrospective study of endometrial cancer (EC) cases from 2 regions of an integrated health care system (Kaiser Permanente Northern (KPNC) and Southern (KPSC) Calif...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.04.692

    authors: Lentz SE,Salyer CV,Dontsi M,Armstrong MA,Hoodfar E,Alvarado MM,Avila M,Nguyen NT,Powell CB

    更新日期:2020-07-01 00:00:00

  • Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.

    abstract:OBJECTIVE:The aim of our study was to retrospectively examine the proliferating cell nuclear antigen (PCNA) immunoreactivity of tumor cells in curettage specimens containing endometrioid adenocarcinoma and obtained immediately before definitive surgical staging. This PCNA index was compared with the one subsequently de...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1996.0089

    authors: Garzetti GG,Ciavattini A,Goteri G,De Nictolis M,Romanini C

    更新日期:1996-04-01 00:00:00

  • Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.

    abstract:OBJECTIVES:Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer, with stage being the most critical prognostic factor. Cervical involvement (CI), divided into IIA (epithelial involvement) and IIB (stromal invasion), is overall associated with decreased survival (...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.03.007

    authors: Orezzoli JP,Sioletic S,Olawaiye A,Oliva E,del Carmen MG

    更新日期:2009-06-01 00:00:00

  • Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection.

    abstract::Women with histopathologically confirmed cervical intraepithelial neoplasia (CIN) were followed at 3-month intervals in a randomized double-blinded trial to evaluate the efficacy of beta-carotene to cause regression of CIN. Questionnaire data, plasma levels of micronutrients, and a cervicovaginal lavage for human papi...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1006/gyno.1997.4697

    authors: Romney SL,Ho GY,Palan PR,Basu J,Kadish AS,Klein S,Mikhail M,Hagan RJ,Chang CJ,Burk RD

    更新日期:1997-06-01 00:00:00

  • The effect of medroxyprogesterone acetate on angiogenesis in complex endometrial hyperplasia.

    abstract:OBJECTIVE:To evaluate the effect of orally administered medroxyprogesterone acetate upon angiogenesis in the myometrium of patients with complex endometrial hyperplasia. METHODS:Microvessel counts in the myometrium of consecutive patients with complex endometrial hyperplasia, treated with oral medroxyprogesterone acet...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5106

    authors: Abulafia O,Triest WE,Adcock JT,Sherer DM

    更新日期:1999-02-01 00:00:00

  • Compliance with research standards within gynecologic oncology fellowship: A Gynecologic Oncology Fellowship Research Network (GOFRN) study.

    abstract:OBJECTIVES:Participation in clinical and basic science research is emphasized in gynecologic oncology training. We sought to identify trends in adherence to expected research practices and reasons for non-adherence among gynecologic oncology fellows. METHODS:An anonymous 31-question online survey assessing academic be...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.06.034

    authors: Moulton LJ,Michener CM,Levinson K,Cobb L,Tseng J,Jernigan A

    更新日期:2017-09-01 00:00:00

  • The reliability of preconization diagnostic evaluation in patients with cervical intraepithelial neoplasia and microinvasive carcinoma.

    abstract::The accuracy of preconization cytology and histology was evaluated in 536 patients undergoing combination laser conization. Exact agreement between cytology and cone diagnosis was observed in 41.8% of the patients. The lowest agreement, 13.6% was demonstrated in cytologic cervical intraepithelial neoplasia (CIN) I, th...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.1995.1281

    authors: Andersen ES,Nielsen K,Pedersen B

    更新日期:1995-10-01 00:00:00

  • Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).

    abstract:PURPOSE:To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. PATIENTS AND METHODS:We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (wee...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.10.031

    authors: Lee JY,Park JY,Park SY,Lee JW,Kim JW,Kim YB,Jeong DH,Lee KB,Kim TH,Lee IH,Choi MC,Kim KH,Kim YM,Lee YJ,Kang S,KGOG Investigators.,Pujade-Lauraine E

    更新日期:2019-01-01 00:00:00

  • Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.

    abstract:OBJECTIVES:MKK4 is a metastasis suppressor that is downregulated in some ovarian cancers. We sought to investigate whether promoter methylation, loss of heterozygosity, or changes in phosphorylation are involved in MKK4 dysregulation during ovarian carcinogenesis. METHODS:Bisulfite sequencing was used to determine MKK...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.12.017

    authors: Spillman MA,Lacy J,Murphy SK,Whitaker RS,Grace L,Teaberry V,Marks JR,Berchuck A

    更新日期:2007-05-01 00:00:00

  • Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial.

    abstract:OBJECTIVE:Minority and low-income cancer patients are underrepresented in clinical trials, contributing to diminished access to state-of-the-art care and disparities in cancer outcomes including survivorship issues. In cervical cancer, there is a disproportionate disease burden among minority and underserved women and ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.ygyno.2011.02.007

    authors: Osann K,Wenzel L,Dogan A,Hsieh S,Chase DM,Sappington S,Monk BJ,Nelson EL

    更新日期:2011-06-01 00:00:00

  • Cervical cancer prevention in remote rural Nicaragua: a program evaluation.

    abstract:BACKGROUND:Nicaragua has some of the highest rates of cervical cancer in Latin America and the world. In 2003, the Nicaraguan Ministry of Health, the Central American Institute of Health and the Maria Luisa Ortiz Clinic combined efforts to create an effective remote rural service network, with centralized quality-contr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.07.094

    authors: Howe SL,Vargas DE,Granada D,Smith JK

    更新日期:2005-12-01 00:00:00

  • Endometrial adenocarcinoma: clinical outcome in 881 patients and analysis of 146 patients whose deaths were due to endometrial cancer.

    abstract::Throughout 1970-1975, 881 patients were treated at Departments I and II of Obstetrics and Gynecology, Helsinki University Central Hospital. They were treated mainly by using surgery and/or radiotherapy combined with adjuvant progestin therapy. The over-all uncorrected 5-year survival rate was 72.2% and corrected rate ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90059-4

    authors: Tiitinen A,Forss M,Aho I,Vesterinen E,Nieminen U

    更新日期:1986-09-01 00:00:00

  • A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.

    abstract::The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer. A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12). Mai...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1006/gyno.1999.5538

    authors: Lhommé C,Vennin P,Callet N,Lesimple T,Achard JL,Chauvergne J,Luporsi E,Chinet-Charrot P,Coudert B,Couette JE,Guastalla JP,Lebrun D,Ispas S,Blumberg J

    更新日期:1999-11-01 00:00:00

  • Reconstructive surgery following resection of primary vulvar cancers.

    abstract:OBJECTIVE:This study describes the surgical treatment and follow-up of 213 patients with primary vulvar cancer; particular attention is given to reconstructive surgical procedures. METHODS:The clinical and pathological parameters of the patients were recorded according to standardized procedures, and the data concerni...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.05.031

    authors: Weikel W,Hofmann M,Steiner E,Knapstein PG,Koelbl H

    更新日期:2005-10-01 00:00:00

  • Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy.

    abstract:OBJECTIVES:To clarify the anatomy necessary for the nerve sparing Okabayashi's radical hysterectomy, we meticulously separated the blood vessels and connective tissues to preserve the pelvic splanchnic nerve, the hypogastric nerve, and the bladder branch of the inferior hypogastric plexus under magnification (x2.5) dur...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.08.076

    authors: Fujii S,Takakura K,Matsumura N,Higuchi T,Yura S,Mandai M,Baba T,Yoshioka S

    更新日期:2007-10-01 00:00:00

  • Management of patients with metastatic gestational trophoblastic tumor.

    abstract:OBJECTIVE:This study was designed to analyze the results of treatment on patients with metastatic gestational trophoblastic tumor (metastatic GTT). METHOD:During 1996-2001, 38 cases with metastatic GTT were diagnosed and received treatment in Vali-e-Asr Hospital, Tehran, Iran. Data were gathered retrospectively and an...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.04.006

    authors: Ghaemmaghami F,Behtash N,Soleimani K,Hanjani P

    更新日期:2004-07-01 00:00:00

  • Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.

    abstract:OBJECTIVES:To evaluate the role of LPA in regulating E-cadherin cell surface expression, adhesion, and invasion in epithelial ovarian carcinoma (EOC) cells. METHODS:E-cadherin mRNA expression in OVCA429 and IOSE-29 cells was evaluated by real-time RT-PCR. Immunofluorescence and Western blot analysis were performed to ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.10.027

    authors: Gil OD,Lee C,Ariztia EV,Wang FQ,Smith PJ,Hope JM,Fishman DA

    更新日期:2008-02-01 00:00:00

  • Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody.

    abstract:OBJECTIVE:To investigate the influence of human anti-mouse antibodies (HAMA) on serial CA 125 measurements in serum of patients with epithelial ovarian cancer following single intraperitoneal (IP) therapy with Yttrium-90-labeled human milk fat globule 1 murine monoclonal antibody ((90)Y-muHMFG1) as part of a large inte...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.ygyno.2008.01.025

    authors: Oei AL,Sweep FC,Massuger LF,Olthaar AJ,Thomas CM

    更新日期:2008-05-01 00:00:00

  • Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.

    abstract:OBJECTIVE:To evaluate testing for high-risk human papillomavirus (HR HPV) E6/E7 mRNA transcripts 6 months after conisation for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) to determine the risk of residual CIN2+. METHODS:We prospectively followed 344 women treated for CIN2+ by conisation. HR HPV mRNA te...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.07.032

    authors: Tropé A,Jonassen CM,Sjøborg KD,Nygård M,Dahl FA,Alfsen GC,Lie AK

    更新日期:2011-11-01 00:00:00

  • The influence of surgical staging on the evaluation and treatment of patients with cervical carcinoma.

    abstract::Ninety-six patients with cervical cancer underwent surgical staging prior to radiation therapy. An equal number of patients were explored by transperitoneal and extraperitoneal surgery. Three different extraperitoneal approaches were utilized. All patients had bilateral paraaortic lymphadenectomy and selective pelvic ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90028-4

    authors: LaPolla JP,Schlaerth JB,Gaddis O,Morrow CP

    更新日期:1986-06-01 00:00:00

  • Simple extrafascial trachelectomy and pelvic bilateral lymphadenectomy in early stage cervical cancer.

    abstract:OBJECTIVE:To determine the feasibility and safety of simple extra-fascial trachelectomy plus pelvic lymphadenectomy in young patients affected by early stage cervical cancer. METHODS:We have prospectively identified all patients with early-stage cervical cancer (stages IA2-IB1) referred to our department. Inclusion cr...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.ygyno.2012.04.004

    authors: Palaia I,Musella A,Bellati F,Marchetti C,Di Donato V,Perniola G,Benedetti Panici P

    更新日期:2012-07-01 00:00:00

  • Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.

    abstract:OBJECTIVE:To evaluate safety, tolerability, and antitumor activity of pembrolizumab monotherapy in patients with programmed death ligand 1 (PD-L1)-expressing advanced ovarian cancer enrolled in the multicohort, phase Ib KEYNOTE-028 trial. METHODS:Key inclusion criteria were age ≥18 years; advanced ovarian epithelial, ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2018.11.017

    authors: Varga A,Piha-Paul S,Ott PA,Mehnert JM,Berton-Rigaud D,Morosky A,Yang P,Ruman J,Matei D

    更新日期:2019-02-01 00:00:00

  • Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

    abstract:OBJECTIVES:Fixed-dose rate gemcitabine plus docetaxel is active as second-line therapy for metastatic uterine leiomyosarcoma. We sought to determine the activity of this regimen as first-line treatment. METHODS:Eligible women with advanced uterine leiomyosarcoma were treated with gemcitabine 900 mg/m(2) over 90 min, o...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2008.03.010

    authors: Hensley ML,Blessing JA,Mannel R,Rose PG

    更新日期:2008-06-01 00:00:00

  • Overall survival after pelvic exenteration for gynecologic malignancy.

    abstract:BACKGROUND:Five-Year survival after pelvic exenteration for gynecologic malignancies has been reported as high as 60%. The objective of this study was to determine overall survival (OS) after pelvic exenteration and evaluate factors impacting outcome. METHODS:A retrospective review of all women who underwent pelvic ex...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.06.034

    authors: Westin SN,Rallapalli V,Fellman B,Urbauer DL,Pal N,Frumovitz MM,Ramondetta LM,Bodurka DC,Ramirez PT,Soliman PT

    更新日期:2014-09-01 00:00:00